Haruo Sugiyama

Haruo Sugiyama

Auto-generated profile, based on publicly available information

Haruo Sugiyama

Osaka University Graduate School of Medicine, Suita, Os, Japan

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 December 2015 in Molecular Carcinogenesis
Verified
Journal Article
Closed access
PDF file
NHNozomi Hojo
Nozomi Hojo
NTNaoya Tatsumi
Naoya Tatsumi
NMNahoko Moriguchi
Nahoko Moriguchi
AMAkihide Matsumura
Akihide Matsumura
SMSoyoko Morimoto
Soyoko Morimoto
Yusuke OjiYusuke Oji
Yusuke Oji

16 February 2022 in Science Translational Medicine
Verified
Journal Article
Open access
KHKana Hasegawa
Kana Hasegawa
SIShunya Ikeda
Shunya Ikeda
MYMoto Yaga
Moto Yaga
KWKouki Watanabe
Kouki Watanabe
RURika Urakawa
Rika Urakawa
NHNaoki Hosen
Naoki Hosen
Cancer-specific cell surface antigens are ideal therapeutic targets for monoclonal antibody (mAb)–based therapy. Here, we report that multiple myeloma (MM), an incurable hematological malignancy, can be specifically targeted by an mAb that recognizes a ubiquitously present protein, CD98 heavy chain (hc) (also known as SLC3A2). We screened more than 10,000 mAb clones raised against MM cells and identified R8H283, an mAb that bound MM cells but not normal hematopoietic or nonhematopoietic cells. R8H283 specifically recognized CD98hc. R8H283 did not react with monomers of CD98hc; instead, it bound CD98hc in heterodimers with a CD98 light chain (CD98lc), a complex that functions as an amino acid transporter. CD98 heterodimers were abundant on MM cells and took up amino acids for constitutive production of immunoglobulin. Although CD98 heterodimers were also present on normal leukocytes, R8H283 did not react with them. The glycoforms of CD98hc present on normal leukocytes were distinct from those present on MM cells, which may explain the lack of R8H283 reactivity to normal leukocytes. R8H283 exerted anti-MM effects without damaging normal hematopoietic cells. These findings suggested that R8H283 is a candidate for mAb-based therapies for MM. In addition, our findings showed that a cancer-specific conformational epitope in a ubiquitous protein, which cannot be identified by transcriptome or proteome analyses, can be found by extensive screening of primary human tumor samples.

1 July 2016 in Clinical Immunology
Verified
Journal Article
Open access
JCJordana Grazziela Alves Coelho-dos-Reis
Jordana Grazziela Alves Coelho-dos-Reis
JHJing Huang
Jing Huang
TTTiffany Tsao
Tiffany Tsao
FPFelipe V. Pereira
Felipe V. Pereira
RFRyota Funakoshi
Ryota Funakoshi
Moriya TsujiMoriya Tsuji
Moriya Tsuji
In the present study, the combined adjuvant effect of 7DW8-5, a potent α-GalCer-analog, and monophosphoryl lipid A (MPLA), a TLR4 agonist, on the induction of vaccine-induced CD8(+) T-cell responses and protective immunity was evaluated. Mice were immunized with peptides corresponding to the CD8(+) T-cell epitopes of a malaria antigen, a circumsporozoite protein of Plasmodium yoelii, and a tumor antigen, a Wilms Tumor antigen-1 (WT-1), together with 7DW8-5 and MPLA, as an adjuvant. These immunization regimens were able to induce higher levels of CD8(+) T-cell responses and, ultimately, enhanced levels of protection against malaria and tumor challenges compared to the levels induced by immunization with peptides mixed with 7DW8-5 or MPLA alone. Co-administration of 7DW8-5 and MPLA induces activation of memory-like effector natural killer T (NKT) cells, i.e. CD44(+)CD62L(-)NKT cells. Our study indicates that 7DW8-5 greatly enhances important synergistic pathways associated to memory immune responses when co-administered with MPLA, thus rendering this combination of adjuvants a novel vaccine adjuvant formulation.

1 January 2010 in International Journal of Medical Sciences
Verified
Journal Article
Open access
MNMiwako Narita
Miwako Narita
MMMasayoshi Masuko
Masayoshi Masuko
TKTohri Kurasaki
Tohri Kurasaki
TKToshiki Kitajima
Toshiki Kitajima
STShoko Takenouchi
Shoko Takenouchi
MTMasuhiro Takahashi
Masuhiro Takahashi
Although tyrosine kinase inhibitors is effective for dramatically reducing CML cells, it might be difficult to eradicate completely the CML stem cells. We aimed to clarify the safety and effects of WT1 peptide vaccination in combination with imatinib therapy for a CML patient. A 51 year-old male with CML in CP, who showed a resistance against imatinib therapy for 2.5 years, began to be treated with 9mer modified-type WT1 peptides in combination with standard dose of imatinib. Although every 2-week-administration of WT1 peptides for 22 weeks did not show definite effects on the quantification of bcr-abl transcripts, by changing the administration from every 2 weeks to 4 weeks bcr-abl transcripts decreased remarkably. After 11 months of every 4-week-administration of the peptides and 12 months post cessation of the peptides bcr-abl transcripts achieved to the level below detection by RQ/RT-PCR (complete molecular response). WT1/MHC tetramer+CD8+ CTLs, which appeared after the second administration of WT1 peptides and remained more than 15 in number among 106 CD8+ T cells throughout the administration of WT1 peptides, are still present in the blood on 14th month post cessation of the peptides. An in vitro study as to the cytotoxicity of lymphocytes induced by mixed lymphocyte peptide culture demonstrated that cultured lymphocytes possessed cytotoxicity against WT1 expressing leukemia cells and the cytotoxicity was WT1-specific and MHC class I restricted. The present study showed that WT1 peptide vaccination in combination with TKI is feasible and effective in the therapy for imatinib-resistant CML.

23 May 2017 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
JNJun Nakata
Jun Nakata
YNYoshiki Nakae
Yoshiki Nakae
MKManabu Kawakami
Manabu Kawakami
SMSoyoko Morimoto
Soyoko Morimoto
DMDaisuke Motooka
Daisuke Motooka
HSHaruo Sugiyama
Haruo Sugiyama

1 January 2009 in Pediatric Hematology and Oncology
Verified
Journal Article
Closed access
HOHideaki Ohta
Hideaki Ohta
YHYoshiko Hashii
Yoshiko Hashii
AYAkihiro Yoneda
Akihiro Yoneda
STSachiko Takizawa
Sachiko Takizawa
SKShigenori Kusuki
Shigenori Kusuki
KOKeiichi Ozono
Keiichi Ozono
Immunotherapy using a Wilms tumor (WT1) peptide has been undergoing clinical trials for adulthood leukemia and solid cancer with promising results. In this study, the authors used WT1 peptide vaccination to treat a 6-year-old girl with metastatic alveolar rhabdomyosarcoma. She received weekly intradermal injection with HLA-A*2404-restricted, 9-mer WT1 peptide against residual bone disease. After 3 months her bone disease disappeared, concurrent with an increase in the frequency of WT1-specific cytotoxic T lymphocytes (CTLs). A high proportion of WT1-specific CTLs with effector or effector memory phenotype were detected in peripheral blood of this patient. She is currently still on continued WT1 peptide immunotherapy in a disease-free condition for 22 months. WT1 peptide-based immunotherapy should be a promising option for high-risk rhabdomyosarcoma in childhood.